December 2020 study revealed that high doses of statins (lipid-lowering medications)
have a synergistic effect on PD-1 immunotherapy treatments yielding better
clinical outcomes for pleural mesothelioma and advanced non-small cell
lung cancer patients.
The study involved statins taken in combination with Opdivo by patients
receiving second or third-line treatment. The response rate was 22% for
patients receiving Opdivo and statins vs. 6% for those not receiving statins.
Progression-free survival was 6.7 months vs. 2.3 months respectively.
A control group of patients who received statins with chemotherapy no
increase in response or survival rates.